Acebrutololum [INN-Latin] en es it fr

Acebrutololum [INN-Latin] Brand names, Acebrutololum [INN-Latin] Analogs

Acebrutololum [INN-Latin] Brand Names Mixture

  • No information avaliable

Acebrutololum [INN-Latin] Chemical_Formula


Acebrutololum [INN-Latin] RX_link

Acebrutololum [INN-Latin] fda sheet

Acebrutololum [INN-Latin] msds (material safety sheet)

Acebrutololum [INN-Latin] Synthesis Reference

No information avaliable

Acebrutololum [INN-Latin] Molecular Weight

336.426 g/mol

Acebrutololum [INN-Latin] Melting Point

119-123 oC

Acebrutololum [INN-Latin] H2O Solubility

259 mg/L

Acebrutololum [INN-Latin] State


Acebrutololum [INN-Latin] LogP


Acebrutololum [INN-Latin] Dosage Forms

Tablet; Capsule (200 mg and 400 mg)

Acebrutololum [INN-Latin] Indication

For the management of hypertension and ventricular premature beats in adults.

Acebrutololum [INN-Latin] Pharmacology

Acebutolol is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. In general, beta-blockers reduce the work the heart has to do and allow it to beat more regularly. Acebutolol has less antagonistic effects on peripheral vascular ß2-receptors at rest and after epinephrine stimulation than nonselective beta-antagonists. Low doses of acebutolol produce less evidence of bronchoconstriction than nonselective agents like propranolol but more than atenolol.

Acebrutololum [INN-Latin] Absorption

Well absorbed from the Gl tract with an absolute bioavailability of approximately 40% for the parent compound. In

Acebrutololum [INN-Latin] side effects and Toxicity

Symptoms of overdose include extreme bradycardia, advanced atrioventricular block, intraventricular conduction defects, hypotension, severe congestive heart failure, seizures, and in susceptible patients, bronchospasm, and hypoglycemia.

Acebrutololum [INN-Latin] Patient Information

Acebrutololum [INN-Latin] Organisms Affected

Humans and other mammals